article · Lymphology
Recurrence remains a significant obstacle in managing lymphatic malformations globally. A ten-year retrospective multi-centre review evaluated clinical records from 2009 to 2019 to identify recurrence risk factors and assess the effectiveness of endovascular and surgical therapies. The study analysed thirteen patients across twenty treatment interventions, tracking recurrence, post-treatment size, and symptom changes. Both surgical procedures and sclerotherapy successfully reduced lesion size and improved symptoms, showing no statistically significant differences in these specific outcomes between modalities. However, surgical resection was linked to the highest recurrence rate at 36.4 percent, whereas lymphaticovenular anastomosis demonstrated favourable outcomes in symptom relief, size reduction, and recurrence rates, although without statistical significance. Furthermore, microcystic lymphatic malformations were identified as an independent risk factor for recurrence. These findings offer practical clinical insight to assist in selecting appropriate interventions and forecasting disease progression.
Lymphatic malformations are complex conditions where lesions frequently return after intervention. Identifying that microcystic lesions carry higher recurrence risks, alongside comparing outcomes between sclerotherapy and surgical approaches, provides valuable guidance. This allows medical practitioners and affected individuals to better anticipate disease behaviour and choose more effective, personalised therapeutic pathways.
The findings primarily inform clinical decision-making protocols and treatment selection for surgeons and interventional radiologists managing vascular malformations. As an applied clinical retrospective study based on a small cohort of thirteen patients, the insights are ready for immediate consideration in specialised clinical practice, though further validation in larger trials may be required before shaping standardised commercial treatment guidelines.
AI-generated from the published abstract. Always read the original work before citing.
Recurrence is a major challenge in treatment of lymphatic malformations (LMs) world-wide. The objectives of the current study were to investigate risk factors associated with LM recurrence and to compare effectiveness of surgical and endovascular treatments. A multi-center 10-year retrospective chart review was conducted on all consecutive patients treated for LMs from 2009 to 2019. Data collected included post-treatment size, symptoms, and recurrence. Stepwise multiple regression analysis was used to identify risk factors and to compare treatment modalities. A total of 13 patients with 20 treatment cases were included. No significant difference was observed in size reduction and symptom alleviation between the treatment groups. Resection showed the highest recurrence rate of 36.4% (p=0.04) and lymphaticovenular anastomosis (LVA) presented excel-lent results in post-treatment size, symptoms, and recurrence despite lack of statistical significance. Microcystic type of LMs was identified as an independent risk factor for recurrence. Both surgery and sclerotherapy are effective in improving size and symptoms of LMs. This data will help physicians and patients choose the optimal treatment and potentially predict progression.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.2458/lymph.8675
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
